3SOF

Quote from: setravis on May 21, 2006, 07:58:37 PM
For every financial reason you shouldn't invest in this company.

Do u mean should?

Quote from: beroznikmal on May 21, 2006, 08:16:15 PM

Quote from: setravis on May 21, 2006, 07:58:37 PM
For every financial reason you shouldn't invest in this company.

Do u mean should?

Yes , should. Thanks for the catch of my typing mistake...
Excuse me for my error....Corrected it on my post. 

wow just trying to help out.. sorry for trying....

Thank you for the help,and excuse me for my typing error... 
Did you misunderstand me?
Applaud for the help....

 

 

Technicals
Record Price High
Percentage Gainer

Last Price Quote is:
10.09%above 13-day EMA
21.63%above 50-day EMA
RS Rating: 98 

Fundamentals
Key Data:
Market Cap (M): $30.56 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Buy

Holding up nice in this market.

Recent CandleStick Analysis
Jun-14-2006 Bullish Engulfing
The last two candlesticks formed a Bullish Engulfing Pattern . This is a bullish reversal pattern that marks a potential change in trend. However, its reliability is not very high and it requires confirmation
White Marubozu
was formed. This shows that the buyers controlled the price action from the first trade to the last trade.

Stochastic is Bullish
MACD is Bearish

Support @ $2.27...2.17...2.07
Resistance  @ $2.39...2.48...2.69...2.88

Technicals
Close Above the 50-day EMA
Close Above the 13-day EMA
Percentage Gainer

Last Price Quote is:
0.22%above 13-day EMA
2.49%above 50-day EMA
RS Rating: 97 

Fundamentals
Key Data:
Market Cap (M): $30.56 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Buy
More...

good analysis starvis...
I was happy to see the white candle today... however not too happy with the volume
Hopefully we'll see more interest tomorrow...
B

The move back to the upside continues.....
Indicators have turned north, MACD..Stochastic..RSI
Broke through minor resistance @ $2.39
Showing a possible buying opportunity as K line is about to cross on top of D line indicating buy signal, while ROC is still at oversold level. One indicator to watch is MACD, MACD is below 0, a weak signal.

Support @ $ 2.39...2.25...2.07
Resistance @ $2.48...2.69...2.89

Volume: 749,300
Avg Vol (3m): 619,118

Technicals
Close Above the 50-day EMA
Close Above the 13-day EMA

MACD is Bearish
Stochastic is Bullish

Last Price Quote is:
7.66%above 13-day EMA
10.10%above 50-day EMA
RS Rating: 97 

Fundamentals
Key Data:
Market Cap (M): $30.56 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Buy

today .. was a good day.. healthy volume...

ISV took a hammering these 3 days..
Technically, there was a bearish raising wedge formation which morphed into a head and shoulder formation.
Fundamentally, Investors are nervous since, Kumar had promised some kind of deal would be made by the end of June and there is only 8 more days left...

B

Press Release Source: InSite Vision Incorporated


InSite Vision to Present Results From Second of Two Pivotal Phase 3 Clinical Trials
Thursday August 3, 9:00 am ET


ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 3, 2006--InSite Vision Incorporated (AMEX:ISV - News), an ophthalmic company focused on ocular infections, glaucoma and retinal diseases, announced today the acceptance of two abstracts related to its second pivotal trial of the topical eye drop antibiotic, AzaSite (1% azithromycin in DuraSite®). The vehicle-controlled, prospective, multi-center, bacterial conjunctivitis trial showed AzaSite was superior to the vehicle in both clinical resolution of the signs and symptoms of bacterial conjunctivitis as well as bacterial eradication. The efficacy and safety data will be presented at the upcoming meeting of the American Academy of Ophthalmology in Las Vegas, Nevada to be held November 11 - 14, 2006. The presentation schedule is as follows:
Efficacy of Azithromycin 1% Eye Drops vs. Vehicle as First-Line Therapy for Bacterial Conjunctivitis, Mark Abelson, MD, Warren Heller, MD, and the AzaSite Clinical Study Group.
Safety and Tolerability of 1% Azithromycin Eye Drops as Anti-infective Therapy for Bacterial Conjunctivitis, Warren Heller, MD, Mark Abelson, MD, and the AzaSite Clinical Study Group.
AzaSite contains 1% azithromycin, a broad-spectrum antibiotic. InSite Vision Inc. has completed two phase 3 studies. The results of these studies were submitted to the FDA on June 28, 2006 as part of the NDA to gain regulatory approval of AzaSite.

The first phase 3 study was a double-blinded, prospective, active-controlled bacterial conjunctivitis trial. It showed AzaSite dosed twice daily for the first 2 days and once daily for 3 more days was equivalent to tobramycin dosed four times daily for 5 days in resolving clinical signs and symptoms of bacterial conjunctivitis and eradicating offending bacteria. The second phase 3 study was a double-blinded, prospective, vehicle-controlled trial. It showed AzaSite was superior to the vehicle in both clinical resolution of the signs and symptoms of bacterial conjunctivitis and bacterial eradication. Both trials revealed a superior safety profile of AzaSite.

Kumar Chandrasekaran, Ph.D., InSite Vision's Chief Executive Officer, stated, "These clinical trial results support AzaSite's value proposition of established efficacy and coverage with the convenience and compliance of a once-a-day dosing regimen."

About InSite Vision Incorporated

InSite Vision is an ophthalmic company focused on developing therapies that treat ocular infections, glaucoma and retinal diseases. The Company's lead product is AzaSite, which targets infections of the eye. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic formulated with DuraSite, InSite Vision's patented drug-delivery vehicle, which offers the benefit of a low-dosing regimen, attractive to both the eye-care patient and physician. Pending the filing and approval of an NDA with the FDA, the Company currently expects AzaSite to be commercially launched in the United States, while seeking to expand this "technology platform" to include additional product candidates and indications for the worldwide market.

In the glaucoma area, the Company continues to focus genomic research on the TIGR gene, among other genes in its genomic portfolio. A portion of this research has been incorporated into the Company's commercially available OcuGene® glaucoma genetic test for disease management, which is a prognostic tool designed to detect a genetic marker (mt-1) in the promoter region of the glaucoma-related TIGR gene.

Additional information can be found at the Company's website, www.insitevision.com.

This news release contains, among other things, certain statements of a forward-looking nature relating to future events or the future business performance of InSite Vision, such as the anticipated closing of the private placement and the proposed use of proceeds therefrom. Such statements entail a number of risks and uncertainties, including but not limited to: InSite Vision's ability to obtain additional financing in the near future, InSite Vision's ability to enroll and complete future clinical trials for AzaSite; the results of InSite Vision's clinical trials, particularly for AzaSite; the ability to complete and file an NDA with the U.S. FDA for AzaSite and its other product candidates, and receive approval from the FDA for the commercialization of AzaSite and its other product candidates; the ability to launch AzaSite and the timing of such a launch; InSite Vision's ability to expand its technology platform to include additional indications and patent options; the effects of its expense control activities on its operations and product development; its ability to obtain regulatory approval and market acceptance of its products and product candidates, including its OcuGene glaucoma genetic test, AzaSite, ISV-205 and ISV-014; InSite Vision's ability to maintain and develop additional collaborations and commercial agreements with corporate partners, including those with respect to AzaSite and ISV-205; its reliance on third parties for the development, marketing and sale of its products; the initiation and results of preclinical and clinical studies; its ability to adequately protect its intellectual property and to be free to operate with regard to the intellectual property of others; determinations by the FDA, including those with respect to OcuGene, AzaSite and ISV-205. Reference is made to the discussion of risk factors detailed in InSite Vision's filings with the Securities and Exchange Commission, including its annual report on Form 10-K and its quarterly reports on Form 10-Q, under the caption "Risk Factors". Any projections in this press release are based on the limited information currently available to InSite Vision, which is subject to change. Although any such projections and the factors influencing them will likely change, InSite Vision undertakes no obligation to update the information. Such information speaks only as of the date of its release. Actual events or results could differ materially and one should not assume that the information provided in this release is still valid at any later date.

Note to Editors: OcuGene® is written with a "small cap" G; if doing so is not possible, please use an upper case G. InSite Vision Incorporated, InSite Vision, DuraSite® and OcuGene® are trademarks of InSite Vision Incorporated. Other trademarks that may be mentioned in this release are the intellectual property of their respective owners.



Contact:
InSite Vision Incorporated
S. Kumar Chandrasekaran or Sandra Heine, 510-865-8800
www.insitevision.com
or
Ashton Partners
888-857-7839 (Investors)
www.ashtonpartners.com

--------------------------------------------------------------------------------
Source: InSite Vision Incorporated

Stochastic coming out of oversold.

Technicals
Percentage Gainer

Last Price Quote is:
8.92%above 13-day EMA
-11.40%below 50-day EMA
RS Rating: 6 

Fundamentals
Earnings Expected on Aug 14

Key Data:
Market Cap (M): $30.56 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Buy

Press Release Source: InSite Vision Incorporated


InSite Vision Announces 2nd Quarter, 2006 Earnings Conference Call to Be Held on August 14, 2006
Monday August 7, 7:00 am ET


ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 7, 2006--InSite Vision Incorporated (AMEX:ISV - News), an ophthalmic therapeutics, diagnostics and drug delivery company, announced today that the company will release 2006 second quarter financial results on Monday, August 14, 2006.


Kumar Chandrasekaran, PhD, Chief Executive Officer, and Sandra Heine, Vice President, Finance and Administration, will host a financial community conference call beginning at 9:00 a.m. EST on Monday, August 14, 2006 to discuss these results.

Individuals interested in listening to the conference call may do so by dialing (877) 407-0778 for domestic callers and (201) 689-8565 for international callers. A telephone replay will be available for 48 hours following the conclusion of the call by dialing (877) 660-6853 for domestic callers and (201) 612-7415 for international callers. All callers will have to enter the conference ID 210914.

The live conference call will also be webcast and available on the Internet at www.InvestorCalendar.com as well as the Company's website at www.insitevision.com. A recording of the call will be available for 90 days following the completion of the conference.

About InSite Vision Incorporated

InSite Vision is an ophthalmic company focused on developing therapies that treat ocular infections, glaucoma and retinal diseases. The Company's lead product is AzaSite, which targets infections of the eye. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic formulated with DuraSite, InSite Vision's patented drug-delivery vehicle, which offers the benefit of a low-dosing regimen, attractive to both the eye-care patient and physician. Pending the filing and approval of an NDA with the FDA, the Company currently expects AzaSite to be commercially launched in the United States, while seeking to expand this "technology platform" to include additional product candidates and indications for the worldwide market.

In the glaucoma area, the Company continues to focus genomic research on the TIGR gene, among other genes in its genomic portfolio. A portion of this research has been incorporated into the Company's commercially available OcuGene® glaucoma genetic test for disease management, which is a prognostic tool designed to detect a genetic marker (mt-1) in the promoter region of the glaucoma-related TIGR gene.

Additional information can be found at the Company's website, www.insitevision.com.

This news release contains, among other things, certain statements of a forward-looking nature relating to future events or the future business performance of InSite Vision, such as the timing of filing an NDA with the FDA, the Company's ability to obtain FDA approval of its NDA and the anticipated date of commercialization of AzaSite. Such statements entail a number of risks and uncertainties, including but not limited to: InSite Vision's ability to enroll and complete future clinical trials for AzaSite; the results of InSite Vision's clinical trials, particularly for AzaSite; the ability to complete and file an NDA with the U.S. FDA for AzaSite and its other product candidates, and receive approval from the FDA for the commercialization of AzaSite and its other product candidates; the ability to launch AzaSite and the timing of such a launch; InSite Vision's ability to expand its technology platform to include additional indications and patent options; the effects of its expense control activities on its operations and product development; its ability to obtain regulatory approval and market acceptance of its products and product candidates, including its OcuGene glaucoma genetic test, AzaSite, ISV-205 and ISV-014; InSite Vision's ability to maintain and develop additional collaborations and commercial agreements with corporate partners, including those with respect to AzaSite and ISV-205; its reliance on third parties for the development, marketing and sale of its products; the initiation and results of preclinical and clinical studies; its ability to adequately protect its intellectual property and to be free to operate with regard to the intellectual property of others; determinations by the FDA, including those with respect to OcuGene, AzaSite and ISV-205. Reference is made to the discussion of risk factors detailed in InSite Vision's filings with the Securities and Exchange Commission, including its annual report on Form 10-K and its quarterly reports on Form 10-Q, under the caption "Risk Factors." Any forward looking statements or projections in the conference call are based on the limited information currently available to InSite Vision, which is subject to change. Although any such forward looking statements or projections and the factors influencing them will likely change, InSite Vision undertakes no obligation to update the information. Such information speaks only as of the date of its release. Actual events or results could differ materially and one should not assume that the information provided in this release is still valid at any later date.

Note to Editors: OcuGene® is written with a "small cap" G; if doing so is not possible, please use an upper case G. InSite Vision Incorporated, InSite Vision, DuraSite® and OcuGene® are trademarks of InSite Vision Incorporated. Other trademarks that may be mentioned in this release are the intellectual property of their respective owners.



Contact:
Ashton Partners
Barry Hutton ,888-857-7839 (Investors)
www.ashtonpartners.com

--------------------------------------------------------------------------------
Source: InSite Vision Incorporated

Broke above the 200-day MA.


Technicals
Close Above the 50-day EMA
Percentage Gainer

Last Price Quote is:
23.19%above 13-day EMA
5.00%above 50-day EMA
RS Rating: 20 

Fundamentals
Earnings Expected on Aug 14

Key Data:
Market Cap (M): $30.56 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Buy